Search

Displaying results 31 - 40 of 204 in total
  1. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  2. Drug

    Butriptyline

    go.drugbank.com/drugs/DB09016
    ApprovedWithdrawn

    Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  4. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    Inositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon.

  5. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    It was approved in Europe in February 2015, and in the United States on March 21, 2017.

  6. Drug

    Protokylol

    go.drugbank.com/drugs/DB06814
    ApprovedVet approved

    Protokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.

  7. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    It is available OTC in Europe.

  8. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties [L1298].

  9. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  10. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.